Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBijal ShahBoston CollegeSCSwetha ChallagullaNational University of MisionesSXSheng XuBeiGene (China)

Discussion

Loading...

Member takes

Overview

Indirect treatment comparison reveals zanubrutinib improves progression-free survival and overall survival versus acalabrutinib in relapsed/refractory mantle cell lymphoma.

Key Points

  • Zanubrutinib treatment is associated with significantly improved progression-free survival, with a hazard ratio of 0.57.
  • The overall survival for zanubrutinib also shows significant improvement, with a hazard ratio of 0.43.
  • An indirect treatment comparison was performed using a simulated treatment comparison method to evaluate the two drugs.
  • Results provide insights into the comparative efficacy of zanubrutinib and acalabrutinib for managing relapsed/refractory mantle cell lymphoma.

Cite This Study

Shah et al. (2025) studied this question.

synapsesocial.com/papers/68bb4d276d6d5674bcd01179https://doi.org/10.1080/10428194.2025.2541911
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma2026
  2. 2An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL2024 · 8 citations
  3. 3Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma2025 · 1 citations
  4. 4Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up2026
  5. 5Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia2026